Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

By H. Hagström, P. Nasr, M. Ekstedt, U. Hammar, P. Stål, R. Hultcrantz, S. Kechagias. Journal of Hepatology, 2017

936 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “16 17 Recently, in a multinational cohort study of 458 adults with biopsy-confirmed NAFLD with advanced fibrosis or compensated cirrhosis, Vilar-Gomez et al found that patients with advanced fibrosis had predominantly CVD events and extrahepatic malignancies, and those with NAFLD-cirrhosis had…”
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. (2020, methodology): “RESULTS: Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.”
Current and future pharmacological therapies for NAFLD/NASH (2017, background): “Given that hepatic fibrosis stage is the most important determinant of mortality in NASH patients [9, 76], there is an unmet medical need for an effective anti-fibrotic treatment for those with advanced fibrosis.”